{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:43:59Z","timestamp":1785401039072,"version":"3.56.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Personalized dosimetry improves overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with glass <jats:sup>90<\/jats:sup>Y radioembolization. This study evaluated personalized tumor dose (TD) as a predictor of OS, progression-free survival (PFS), and local duration of response (DOR) in patients with surgically unresectable HCC treated with resin <jats:sup>90<\/jats:sup>Y radioembolization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This prospective, single-center, single-arm clinical trial (NCT04172714) evaluated the efficacy of scout activity of resin <jats:sup>90<\/jats:sup>Y versus <jats:sup>99m<\/jats:sup>Tc-MAA for treatment planning. A secondary aim of this study was to evaluate personalized dosimetry as a predictor of OS, PFS, and DOR. Partition dosimetry model was utilized for nonsegmental therapies with targeted TD &gt;200 Gy and nontumoral liver dose &lt;70 Gy. Single compartment dose of 200 Gy was used for segmentectomies. OS, PFS, and local DOR from <jats:sup>90<\/jats:sup>Y was estimated using Kaplan-Meier estimation with log-rank analysis used to determine predictors of prolonged survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings<\/jats:title>\n            <jats:p>Thirty patients with treatment-naive HCC and 33 tumors (19 segmental and 14 nonsegmental) were included. Overall, 18 patients underwent segmental Y90-RE and 12 underwent non-segmental\/lobar therapies. The mean <jats:sup>90<\/jats:sup>Y TD was 493 Gy. The median follow-up since enrollment into the study was 37 months. The mean OS was 32.2 months for the entire cohort. A total of 5 patients underwent orthotopic liver transplantation post <jats:sup>90<\/jats:sup>Y and were excluded from further survival analysis. The mean OS for the remainder of the cohort was 30.1 months (median not reached). The mean TD &gt;250 Gy resulted in prolonged mean OS and PFS. The median local DOR was 32.7 months with mean TD 330 Gy predicting prolonged DOR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation<\/jats:title>\n            <jats:p>For patients with surgically unresectable HCC treated with resin <jats:sup>90<\/jats:sup>Y, there is mean TD threshold predicting prolonged OS, PFS, and local DOR. Therefore, there should be further emphasis on personalized dosimetry for optimization of patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005198","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T17:07:07Z","timestamp":1718125627000},"page":"799-805","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Resin-Based 90Y Tumor Dose as a Predictor of Duration of Response and Survival in Patients With Surgically Unresectable Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"49","author":[{"given":"Nima","family":"Kokabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzi A.","family":"Webster","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Dabbous","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brandon","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galt","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Xing","sequence":"additional","affiliation":[{"name":"Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Villalobos","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Davarpanahfakhr","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cheenu","family":"Kappadath","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, MD Anderson Cancer Center, University of Texas at Houston, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","year":"2022","journal-title":"J Hepatol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jvir.2022.08.027","article-title":"Accuracy and safety of scout dose resin Yttrium-90 microspheres for radioembolization therapy treatment planning: a prospective single-arm clinical trial","volume":"33","year":"2022","journal-title":"J Vasc Interv Radiol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","article-title":"Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","year":"2020","journal-title":"J Hepatol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","article-title":"Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study","volume":"296","year":"2020","journal-title":"Radiology"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00259-013-2674-6","article-title":"The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE)","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","article-title":"Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","article-title":"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study","volume":"5","year":"2023","journal-title":"JHEP Rep"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:03:02Z","timestamp":1750532582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005198"}},"subtitle":["A Prospective Single-Arm Study"],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005198","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}